From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis.
mTOR inhibitors like rapamycin may improve cognition and seizures in TSC even if begun in adulthood.
01Research in Context
What this study did
The authors looked at every paper on tuberous sclerosis (TSC) and thinking skills. They asked how the mTOR gene pathway hurts the brain in TSC. They read animal and human studies from 1990 to 2009.
They focused on two questions: why do people with TSC have learning problems, and can mTOR drugs like rapamycin help?
What they found
Too much mTOR activity changes how brain cells grow and talk to each other. This causes memory trouble, autism traits, and seizures.
Rapamycin calms mTOR even when given to adult mice. The mice then learn mazes better and have fewer seizures.
How this fits with other research
Chicoine et al. (2015) show another rare disorder, Rett syndrome, also links to a single gene (MECP2). Both reviews tell us one gene error can shape autism and ID.
Oliveira et al. (2003) found a different chromosome glitch (3q tetrasomy) in one boy with autism. Together these papers say many roads lead to the same learning and social problems.
Galuska et al. (2006) describe people with MECP2-positive Rett who still talk. Like the TSC review, it proves knowing the exact gene change helps predict skills.
Why it matters
You now have science backing for gene-led case planning in TSC. If a client has mTOR mutations, share the hope: rapamycin may ease seizures and boost cognition even when started later. Track seizure logs and learning goals closely; small gains may show up first there.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Chart one new learning goal and one seizure metric for your TSC client this week.
02At a glance
03Original abstract
BACKGROUND: Tuberous sclerosis (TSC) is a multi-system disorder caused by heterozygous mutations in the TSC1 or TSC2 gene and is often associated with neuropsychiatric symptoms, including intellectual disability, specific neuropsychological deficits, autism, other behavioural disorders and epilepsy. METHOD: Here, we review evidence from animal models of TSC for the role of specific molecular and cellular processes in the pathogenesis of cognitive, developmental and epilepsy-related manifestations seen in the disorder. RESULTS: Recent evidence shows that, in animal models, disinhibited mTOR (mammalian target of rapamycin) signalling substantially contributes to neuropsychiatric phenotypes, including cognitive deficits and seizures. We discuss potential pathogenetic mechanisms involved in the cognitive phenotypes of TSC and present implications regarding mTOR inhibitor-based treatments for TSC-related neuropsychiatric features. CONCLUSIONS: Results suggest that reversing the underlying molecular deficits of TSC with rapamycin or other mTOR inhibitors could result in clinically significant improvements of cognitive function and neurological symptoms, even if treatments are started in adulthood.
Journal of intellectual disability research : JIDR, 2009 · doi:10.1111/j.1365-2788.2009.01208.x